Kristin Yarema Ph.D.
Net Worth

Last updated:

What is Kristin Yarema Ph.D. net worth?

The estimated net worth of Dr. Kristin Yarema Ph.D. is at least $4,313,251 as of 14 Jun 2021. He owns shares worth $1,510,571 as insider and has received compensation worth at least $2,802,680 in Atara Biotherapeutics, Inc..

What is the salary of Kristin Yarema Ph.D.?

Dr. Kristin Yarema Ph.D. salary is $700,670 per year as SVice President & Chief Commercial Officer in Atara Biotherapeutics, Inc..

How old is Kristin Yarema Ph.D.?

Dr. Kristin Yarema Ph.D. is 54 years old, born in 1971.

What stocks does Kristin Yarema Ph.D. currently own?

As insider, Dr. Kristin Yarema Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Atara Biotherapeutics, Inc. (ATRA) SVice President & Chief Commercial Officer 125,882 $12 $1,510,571

What does Atara Biotherapeutics, Inc. do?

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

ATRA logo
ATRA
Atara Biotherapeutics, Inc.
$12

Kristin Yarema Ph.D. insider trading

Atara Biotherapeutics, Inc.

Dr. Kristin Yarema Ph.D. has made only one insider trade in 2021, according to the Form 4 filled with the SEC. He purchased 32,333 units of ATRA stock worth $469,798 on 14 Jun 2021.

As of 14 Jun 2021 he still owns at least 125,882 units of ATRA stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 32,333 $14.53 $469,798
Purchase
Common Stock 2,021 $14.5 $29,305
Sale
Common Stock 761 N/A N/A

Atara Biotherapeutics key executives

Atara Biotherapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. Jakob Dupont (60) Head of Global R&D
  • Dr. Kristin Yarema Ph.D. (54) SVice President & Chief Commercial Officer
  • Dr. Pascal Touchon D.V.M. (62) Pres, Chief Executive Officer & Director
  • Mr. Joseph Newell (55) Executive Vice President & Chief Operating Officer
  • Mr. Utpal Koppikar (54) Chief Financial Officer & SVice President